Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 18/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19398558 | 0.84 | MAP4K4 (0.61) | MAP4K4 | |
| SCHEMBL15587273 | 0.83 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL182771 | 0.83 | PIK3CD (0.73) | MAP4K4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3337591 | 0.83 | PIK3CA (0.62) | MAP4K4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL180943 | 0.82 | ENPP1 (0.55) | MAP4K4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3335439 | 0.82 | BRAF (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL182889 | 0.82 | PIK3CD (0.67) | MAP4K4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4355479 | 0.81 | CLK4 (0.60) | — | |
| SCHEMBL7153509 | 0.81 | PDGFRB (0.57) | MAP4K4PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL15587269 | 0.81 | MAP4K4 (1.00) | MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855459-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | claimed |
| WO-2013178591-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | claimed |
| US-20130324516-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH INC (US) | 2013-12-05 | — | — | US | claimed |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | claimed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-2855459-B1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9382241-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9259426-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2855459-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| CN-104507933-A | Aminoquinazoline and pyridopyrimidine derivatives | HOFFMANN LA ROCHE | 2015-04-08 | — | — | CN | disclosed |
| WO-2013178591-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
| WO-2013178591-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
| US-20130324516-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH INC (US) | 2013-12-05 | — | — | US | disclosed |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324516-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | ABL1, CDK2, PDXK | MAP4K4 142/4885PIK3CD 1370/4885PIK3CA 1073/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | MAP4K4 1801/4885PIK3CD 4161/4885PIK3CA 3986/4885 |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | MAP4K4 662/4885PIK3CD 1616/4885PIK3CA 957/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | MAP4K4 1801/4885PIK3CD 4161/4885PIK3CA 3986/4885 |
| US-20090285782-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR5A2, NR4A1 | MAP4K4 1921/4885PIK3CD 4183/4885PIK3CA 4078/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | MAP4K4 1837/4885PIK3CD 3942/4885PIK3CA 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.